Brain Cancer and Medicinal Cannabis
Preclinical cannabinoid research in brain cancer, the limited state of clinical evidence, and separate consideration of symptom and supportive-care research.
- Duration
- 40 minutes + quiz
- Instructor
- Assoc Prof Janet Schloss (Australia)
- Learning format
- Module
- Status
- Available now
12-month access from confirmed payment. Certificate of completion included.
One-time payment in USD. Access begins after confirmed payment and continues for 12 months. Refunds are available before access begins, subject to mandatory consumer rights.
Purchase ModuleBy selecting Purchase Module, you acknowledge the Terms and Conditions, including USD pricing, applicable taxes, the pre-access refund policy and 12-month access period.
A certificate records completion only; it is not a qualification, licence, specialist credential or accreditation. Read the complete Terms and Conditions.
Educational content only. Not medical advice. Practitioners are responsible for compliance with local law.
Preclinical cannabinoid research in brain cancer, the limited state of clinical evidence, and separate consideration of symptom and supportive-care research.
- Distinguish preclinical anticancer findings from evidence of clinical effectiveness in people.
- Discuss the separate evidence and safety considerations relevant to supportive care.
- 01Recorded lecture
A 40-minute lecture delivered by the module educator.
- 02Assessment quiz
A short quiz assessing understanding of the key learning points.
Relevant conflicts of interest, where applicable, are disclosed within the course materials.
Is this module part of a course?+
No — this is a standalone specialised module.
When can I access it?+
This module is available now. Access begins after confirmed payment and continues for 12 months.
Are certificates provided?+
A certificate of completion records completion of the educational activity. It is not a professional qualification, licence, specialist credential or accreditation unless expressly stated otherwise.